Dear friends, dear colleagues
A few weeks ago, we announced that we were continuing to work on EANO 2020, hoping that by September 2020 the circumstances would allow this major European neuro-oncological event to happen. However, it is clear that even now when restrictions are gradually lifted many uncertainties about the COVID infection rate will remain over the entire summer period. Unpredictable travel limitations, unclear national policies on mass gatherings, and the chance of yet another surge in COVID infections make a productive and successful face-to-face EANO 2020 in early September unlikely. Therefore, we have taken the difficult decision to postpone the EANO 2020 Meeting in Glasgow to another year.
We have decided to develop a series of webinars instead, called eEANO, through which we will bring neuro-oncological updates to the EANO membership. These will start on September 10-13, the original dates of EANO 2020. We will continue eEANO as a series of webinars afterwards, which will be CME credited, for members only. We intend to provide both educational content and the latest scientific developments on clinical trials and laboratorial research as a continuing programme. Topics will be developed in collaboration with the membership. More information will be provided once we have finalized the details. The next planned EANO Meeting should take place in 2021. We will keep you posted on that situation and very much hope to welcome you to a ‘face-to-face’ conference next year.
I am very sorry not to see you in person in Glasgow this summer; not meeting colleagues is yet another loss that many of us deplore. I also apologize for not informing you earlier, but as you can imagine it has been complicated to reach a good solution with regard to the practical issues. Lastly, I want to recognize the many people who have worked hard to prepare the 2020 meeting, in particular our local chair Anthony Chalmers. EANO is scheduled to come to Glasgow in 2024!
On behalf of the EANO board,
Martin van den Bent
The EANO Executive Board is glad to present this year's EANO Annual Report. It gives you an overview on what we have done during 2019 and on our planned activities for 2020 as well as important developments in Neuro-Oncology in Europe.
For the new EANO Annual Report 2019 click here
According to the EANO Youngsters
The EANO Youngsters selected the most important scientific neuro-oncology papers of 2019. Instead of just looking at the number of citations or impact factors, we performed a survey in our EANO Youngsters Facebook group. We received a lot of input! We now have an interesting impression of which studies our followers were most interested in this year.
This year's list features important basic science papers, published in high-impact journals, and possible practice-changing clinical papers.
So, here are our top 6 paper:
- Suva group's single cell paper: Neftel C. et al. (2019) An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. Cell, 178(4):835-849.e21. doi: 10.1016/j.cell.2019.06.024. https://www.ncbi.nlm.nih.gov/pubmed/31327527
- The Nature-trio on synaptic interactions between glioma cells and neurons: Barrier A. Dangerous liaisons as tumour cells form synapses with neurons. Nature (2019) 573, 499-501, doi: 10.1038/d41586-019-02746-7 https://www.nature.com/articles/d41586-019-02746-7
- Taylor group's snRNA paper: Suzuki H. et al. . Recurrent non-coding U1-snRNA mutations drive cryptic splicing in Shh medulloblastoma. Nature. (2019). doi: 10.1038/s41586-019-1650-0. https://www.ncbi.nlm.nih.gov/pubmed/31597162
- Exciting work from the Glioma Longitudinal Analysis (GLASS) Consortium: Barthel, F.P., Johnson, K.C., Varn, F.S. et al. Longitudinal molecular trajectories of diffuse glioma in adults. Nature (2019) doi:10.1038/s41586-019-1775-1 https://www.nature.com/articles/s41586-019-1775-1
- Whole brain radiotherapy with or without hippocampal avoidance in brain metastases: Tomé W. et al. RADI-11. NRG ONCOLOGY CC001: A PHASE III TRIAL OF HIPPOCAMPAL AVOIDANCE IN ADDITION TO WHOLE-BRAIN RADIOTHERAPY (WBRT) PLUS MEMANTINE TO PRESERVE NEUROCOGNITIVE FUNCTION IN PATIENTS WITH BRAIN METASTASES (BM), Neuro-Oncology Advances, Volume 1, Issue Supplement_1, August 2019, Pages i23–i24, doi.org/10.1093/noajnl/vdz014.104 https://academic.oup.com/noa/article/1/Supplement_1/i23/5546283
- Lomustine-temozolomide or standard temozolomide therapy in glioblastoma: Herrlinger U. et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. The Lancet (2019) 393 (10172), P678-688, doi.org/10.1016/S0140-6736(18)31791-4 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31791-4/fulltext?dgcid=raven_jbs_etoc_email
Dear friends and colleagues,
It was a great pleasure to welcome all of you in Lyon, and make the EANO 2019 a great meeting increasing our knowledge to take care of patients with brain tumors. More than 750 participants from 50 different countries and from all the continents participated to the 14th EANO meeting. All the specialties were equally represented with a good percentage of nurses. The scientific presentations showed up a large variety of important subjects in the field of neuro-oncology and was the opportunity to listen to high level lectures about immunology, low-grade glioma, omics in neuro-oncology, microenvironment, neurological complications of cancer or brain lymphoma. It was also wonderful to see the involvement of young neuro-oncologists in the EANO meeting and organization. The diversity of age and origin of the participants is really a good sign that EANO annual meetings have become a meeting for everybody and able to attract colleagues from all continents.
The 14th EANO meeting was also the opportunity to discover Lyon, a European city at the crossroads of Europe, listed by UNESCO as a world heritage site with the remains of 20 centuries of History. The participants discovered the high level of gastronomy of the city with its 14 starred restaurants and to the typical and charming bistros called “Bouchons”. The networking evenings have been the opportunity to visit the City Hall and to have a wonderful cruse with a seated dinner on the Rhone and the Saone.
We were very happy when France and Lyon were given the responsibility for EANO 2019, and it has been a real pleasure to interact with all the members of the EANO executive Board and the EANO scientific committee to construct the program and to organize the meeting.
Many thanks for your contribution and I will be very happy to meet you in Glasgow in September 2020.
Jérôme Honnorat, President EANO 2019 Meeting
EANO members can find a large selection of presentations from the EANO 2019 Meeting online in the login area!
The European Association of Neuro-Oncology (EANO) and Society for NeuroOncology (SNO) the are pleased to announce that their journal, Neuro-Oncology Practice, is now fully indexed in PubMed Central® (PMC). All content published in Neuro-Oncology Practice, starting with the first issue, has been deposited in PMC and is now discoverable through PubMed®. PMC is a free archive of biomedical and life sciences journal literature at the U.S. National Institutes of Health's National Library of Medicine (NIH/NLM).
Indexing in PMC and discoverability via PubMed provides increased access to articles for the scientific and clinical communities, and marks its continued success, high-quality articles, and the diversity and excellence of the editorial board and authors. The Journal can be accessed here: https://academic.oup.com/nop (includes Advance Access articles), and can also be accessed on the PMC site here: https://www.ncbi.nlm.nih.gov/pmc/journals/2697/
“It has been great to partner with SNO, EANO and OUP to grow the journal and provide the neuro-oncology community with valuable resources pertinent to patient care,” said Dr Susan Chang, Editor in Chief of Neuro-Oncology Practice and Professor of Neurological Surgery at the University of San Francisco, CA, United States, “I know authors and readers will be happy that articles from Neuro-Oncology Practice will be discoverable via PubMed.”
Published in partnership with Oxford University Press, Neuro-Oncology Practice focuses on the clinical aspects of the subspecialty for practicing clinicians and healthcare specialists from a variety of disciplines including physicians, nurses, physical/occupational therapists, neuropsychologists, and palliative care specialists, who have focused their careers on clinical patient care and who want to apply the latest treatment advances to their practice.
For more information and to submit a manuscript for consideration, visit https://academic.oup.com/nop and follow the journal via Twitter at https://twitter.com/neuroonc and at https://twitter.com/eanoassociation